Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Sodium Glycerophosphate and Numeta G16%E in Healthy Volunteers
NCT06842134Phase 1Completed
- Sponsor
- Baxter
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium glycerophosphate in hypophosphatemia (2 arms), sponsored by Baxter. Primary endpoints: Baseline-corrected maximum observed concentration (Cmax) for inorganic phosphate and Baseline-corrected area under the curve from time 0 to 24h post-dose (AUC0-24) for inorganic phosphate. Started Jan 2025; status: completed.
02
Drugs
sodium glycerophosphate
03
Conditions
hypophosphatemia
Beyond the preview
Go deeper on NCT06842134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842134.